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Summary.-Attempts were made to induce immunity to 5 spontaneous rat sarcomas
transplanted into syngeneic recipients. Rats were immunized by surgical removal of
growing tumour transplants or by treatment with attenuated tumour, followed by
challenge with tumour cells in suspension. Two tumours were apparently not
immunogenic, but a low level of immunity was induced against2, and weak evidence
of immunity was observed with another. Induced immunity was individually specific
rather than cross-reactive. It is concluded that, contrary to some reports, some
spontaneous animal tumours are immunogenic in the strain of origin.
IN RECENT YEARS attention hCas been1
drawn to the merits or otherwise of spon-
taneous animal tumours compared with
artificially induced ttumours in experi-
mental cancer research, particularly in the
study of tumour immunology (Hewitt et
al., 1976; Martin et al., 1977; Klein &
Klein, 1977). It is widely accepted that
most virus-induced tumours and many
chemically induced tumours have specific
antigens capable of inducing a tumour
rejection response in suitably immtunized
inbred animals (Klein & Klein, 1977;
Embleton & Baldwin, 1980). Truly spon-
taneous tumours, on the other hand, tend
to be deficient in this property, and this
has led to criticism of the use of experi-
mentally induced tumour models, on the
grounds that they do not represent a
natural situation (Hewitt et al., 1976:
Hewitt, 1978).
Discounting tumours arising within
high-tumour-incidence animal strains or
those with a known viral aetiology, there
is a sparse literature on the immunology
of spontaneous animal tumours, possibly
owing to their infrequent occurrence in
normal laboratory animal populations.
The earliest report was that of Prehn &
Main (1957), in which it, was clearly shown
that mice immmunized against syngeneic
3-methylcholanthrene-induced sarcomas
by amputation of a tumour-bearing limb
were resistant to grafts of the same
tumour, but mice similarly immunized
against spontaneously arising sarcomas
were not immune to rechallenge. It is
possible that the challenge graft overcame
any weak responses to the spontaneous
tumours, and Hammond et al. (1967)
demonstrated weak immunity against
spontaneous murine fibrosarcomas and
myoepitheliomas, using a similar method
of immunization but low numbers of dis-
persed cells as challenge inocula. Hewitt,
et al. (1976) published results of a long-
term study in which 27 spontaneous
murine tumours of various types were
evaluated for their transplantation charac-
teristics in experimental circumstances
where tumour-immune responses might,
be detected, though many of the experi-
ments were not originally designed for this
purpose. No clear evidence for tumour-
immune responses was obtained, and it
was concluded that these tumours lacked
antigens capable of evoking transplanta-
tion immunity in syngeneic hosts.
Spontaneous tumours of other labora-
tory animals conform to a similar pattern.
Thus Baldwin (1.966) was able to demon-
strate significant immunity to a spon-IMMUNITY TO RAT SARCOMAS
taneous rat squamous-cell carcinoma, but
was unable to detect any response to a
reticulum-cell sarcoma in immunized rats.
Baldwin & Embleton (1969) examined 9
spontaneous rat mammary carcinomas,
andfoundone ofthese to be fairly strongly
immunogenic, 2 only weakly immuno-
genic and the other 6 apparently non-
immunogenic in syngeneic rats. A spon-
taneous rat leukaemia (Wrathmell &
Alexander, 1976) and spontaneous ham-
ster lymphomas (Vasa-Thomas et al.,
1977) have been reported to be weakly
immunogenic in the inbred strain of
origin.
Thus the literature suggests that some
spontaneous tumours have tumour-asso-
ciated antigens capable of inducing im-
munity to challenge, though these may be
in the minority. Our work over the past
few years reinforces this view, and the
present paper reports the demonstration
of immunogenicity of a small number of
spontaneous rat sarcomas.
MATERIALS AND METHODS
Animals.-Inbred WAB/Not rats were
used. They have been bred, from an originally
inbred colony, by continuous brother-sister
mating for 50 generations. These rats accept
skin grafts between individuals of the same
sex.
Tumours.-Five primary sarcomas (Sp7.
Sp20, Sp24, Sp25 and Sp4l) arose without
deliberate induction in male breeding rats.
They all arose before June 1976 and were
transplanted s.c. into syngeneic male rats and
maintained as serially propogated lines. In
addition, transplant lines were established
from 2 lymph-node metastases of Sp25,
designated Sp26 and Sp27 respectively.
Samples ofall tumours at various generations
of transplantation were stored in liquid N2.
They were transplanted back into syngeneic
male rats as required, after rapid thawing at
370C.
Immunization.-Syngeneic male rats were
immunized against transplanted tumours
using one of the following techniques:
(a) Tumour fragments were transplanted
s.c. and allowed to grow to a mean diameter
of - 1-5 cm. The tumour, complete with its
overlying skin, was then surgically removed
and the wound was sutured with stainless-
steel clips.
(b) Tumour fragments or cells in suspension
were y-irradiated (150 Gy) on a 60Co source.
Solid fragments were grafted s.c. and cells
were injected s.c. or i.m. as indicated in the
text. Usually 3-5 doses ofirradiated tissue or
cells were given at about 2-week intervals.
(c) Tumour-cell suspensions were fixed in
10% formal saline for 30 min, washed x 4 in
Hanks' balanced salt solution (HBSS) and
injected s.c. or i.p.
(d) Tumour cells were incubated for 30 min
at 37°C with mitomycin C at a concentration
of 80 ,ug/ml in HBSS. They were then in-
jected i.p. either as a single dose or as 5
weekly doses.
(e) Tumour cells were mixed with BCG
(Glaxo Percutaneous BCG vaccine) or Coryne-
bacterium parvum (Wellcome Reagents Ltd)
as indicated in the text, and administered by
s.c. injection. Either a single injection or 4
weekly injections were given.
Tumour challenge.-Seven to 10 days after
the final immunizing inoculum the rats were
challenged with tumour cells brought into
suspension by trypsinization (Baldwin, 1966).
The challenge inocula were given s.c. in most
cases, but in some experiments they were
given by other routes (i.p., i.m. or i.v.) as
indicated in the text.
Growth of tumour inocula was monitored
weekly. Tumours growing s.c. were measured
with calipers in 2 perpendicular planes to
provide an indication of growth rate. At the
end of experiments involving i.v. challenge
inocula, the lungs were removed for estima-
tion of surface tumour nodules. The lungs
were inflated with an aqueous suspension of
India ink injected via the trachea, washed in
running water and fixed in Fekete's solution.
Tumour nodules were easily visible against
the normal lung surface.
Initially, challenge inocula were given at a
low cell dose and if this failed to produce
tumours the experimental rats were re-
challenged with a higher cell dose about 6
weeks later. This was repeated until challenge
tumours grew progressively in immunized
rats, a new untreated control group being
used each time. This procedure was adopted
to prevent possible overwhelming of weak
immune responses by large initial challenge
inocula. In some experiments sham-operated
controls were used in addition to untreated
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TABLE I.-Subcutaneous challenge with transplanted sarcomas of spontaneous origin, in
syngeneic rats immunized by surgical excision of s.c. tumour grafts
Trar
Tumour gene
Sp7
Sp2O
Sp24
Sp25t
Sp26t
Sp27t
Sp4l
Immunizing graft
Duration
isplant of growth Cell
3ration (days) dose
1 15 103
104
105
15 13 2x104
105
22 11 2x104
5x 104
105
2 x 105
2 17 104
5 x 104
2 x 105
2 18 103
104
1 14 104
1 15 104
1 16 104
5 x 144
1 15 104
105
5 x 105
9 9 105
Challenge inocula Tumour incidence
A -
Transplant
generation
2
2
3
16
19
25
31
36
44
3
3
3
4
7
2
2
2
4
2
3
4
10
Tumour
excised
0/3
1/3
2/2
0/5
0/5
0/4
0/4
1/4
0/3*
0/6
0/6
6/6
1/5
3/4
5/5
5/5
0/5
4/5
0/5
3/5
2/2
0/4
Sham-
operated
0/6
2/6
3/4
ND
ND
ND
ND
ND
ND
0/4
0/4
4/4
3/4
1/1
5/5
5/t
0/5
5/5
ND
ND
ND
ND
Untreated
controls
NDt
1/4
4/4
2/4
4/4
4/4
5/6
6/6
5/6
0/4
0/4
4/4
ND
3/4
ND
ND
ND
4/4
0/5
2/5
5/5
4/4
* One rat died without evidence of tumour growth.
t Tumours Sp25, Sp26 and Sp27 arose in the same primary host. Sp26 and Sp27 were located in lymph
nodes and were probably metastases of Sp25.
$ Not done.
controls, and implantation of irradiated
normal liver, kidney and spleen was per-
formed to control immunization with irradi-
ated tumour.
Where differences were observed between
tumour growth in immunized rats and in
controls, a 2-tailed Wilcoxon rank test was
applied to determine their significance.
RESULTS
The response to immunization by sur-
gical resection of growing tumour is
shown in Table I. Tumours Sp7 and Sp4l
were tested both at early and late trans-
plant generations, and all other sarcomas
were tested as early transplants. With
sarcoma Sp24, 103 cells grew slightly less
well in immunized rats than controls, but
this difference was insignificant and was
overcome by a subsequent challenge with
104 cells. No response could be detected
against Sp7 and Sp41 at the earliest trans-
plant generations, but at later generations
it was possible to demonstrate resistance
to challenges which grew in all control
rats. At first sight this suggests antigenic
divergence following transplantation, but
subsequent results (Table II) cast doubts
upon such a conclusion. The remaining
tumours (Sp2O, Sp25 and its sublines Sp26
and Sp27) were apparently completely
non-immunogenic, as judged by growth
of challenge inocula in rats immunized by
tumour excision (Table I).
The immunogenicity of irradiated (150
Gy) tumour grafts is shown in Table II.
In this case Sp7 and Sp4l induced im-
munity to challenge at early generations
of transplantation, though Sp7 was less
immunogenic at intermediate generations,
where immunization by tumour excision
was successful (Table I), perhaps suggest-
ing transient radiosensitivity of the anti-
gens responsible. The positive immune
Pvs
immun-
ized
<0-02
<003
<0*02
<005
<005
<003
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TABLE II.-Subcutaneous growth of transplanted sarcomas of spontaneous origin in
syngeneic rats pre-immunized with irradiated (150 Gy) s.c. tumour grafts
Challenge inocula
No. of Transplant Cell
Tumour grafts generations dose
Sp7 4 1-2 103
104
105
5x 105
4 5-6 103
104
105
2 x 105
4 7-8 104
105
4x 105
4 18,20-22 2x104
5x 104
105
2x 105
5x 105
106
Sp2O 5 1-3 104
5x 104
2x 105
Sp24 4 2-5 103
104
5 37-39,41,46 2 x 104
5x 104
Sp25 4 1-3 5 x 104
Sp26 4 1-3 104
Sp27 4 1-3 5 x 104
Sp4l 3 1-2 103
104
105
5x 105
4 17-20 5 x 104
4x 105
Transplant
generations
2
3
4
5
7
7
9
9
9
10
11
23
31
36
40
44
51
3
3
3
6
7
47
52
3
3
4
2
3
4
5
21
19
Tumour incidence
Tumour Normal
immun- tissue Untreated
ized treated controls
0/6 0/6 0/6
0/6 1/6 0/6
0/1* 4/5 < 0 04 6/6
4/4* 1/1 6/6
0/6 1/6 0/5
1/6 0/5 2/5
3/5 5/5 2/4
2/2 ND 4/4
0/6 1/5 1/4
2/6 2/4 2/4
3/4 2/2 4/4
Q/6 ND 2/4
0/6 ND 3/6
0/5* ND 6/6
0/5 ND 6/6
0/4* ND 5/5
0/4 ND 6/6
0/5 0/4 0/4
0/5 0/4 0/4
5/5 4/4 4/4
0/5 0/4 0/4
5/5 2/4 3/4
2/6 ND 4/4
2/2 ND 6/6
5/5 5/5 4/4
5/5 4/4 5/5
5/5 5/5 5/5
0/5 0/5 0/5
0/5 0/5 0/5
0/5 5/5< 0-01 2/5
5/5 ND 5/5
1/5 ND 4/4
2/4 ND 4/4
* One rat died without evidence of tumour growth.
response to Sp7 at early generations has
been confirmed independently (C. R.
Barker, unpublished). There was again a
weak indication of a response to Sp24 in
one experiment using late-generation
tumour transplants, but this was not
statistically significant. No immunity
could be induced against Tumours Sp2O,
Sp25, Sp26 or Sp27. Some experiments
included control groups treated with
irradiated fragments of normal liver,
kidney and spleen. Where included, these
rats behaved in a similar fashion to un-
treated controls.
Further experiments were undertaken
with the immunogenic tumours to deter-
4
mine the optimum methods of immuniza-
tion and challenge in order to demonstrate
challenge resistance. Rats were immunized
by graft excision or by irradiated tumour,
and challenged with cells of the immun-
izing tumour administered by several
different routes (s.c., i.p., i.m. and i.v.)
(Table III). With Sp7 and Sp4l, compari-
son between different routes of challenge
indicated that the s.c. and i.p. routes gave
the greatest differential between immun-
ized and control rats. Of these 2 routes,
s.c. challenge was considered preferable
because tumour growth rate can be
assessed by caliper measurements in addi-
tion to merely recording presence or
Immunizing grafts
A
P V8
immun-
ized
< 0-01
< 0-01
< 0-01
< 0-01
< 0-01
<0*05
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TABLE III.-Growth of transplanted spontaneous rat sarcomas after immunization and
challenge by different routes
Immunization Challenge inocula Tumour incidence
C-
Transplant Cell Transplant Immunized Untreated
Tumour Method*
Sp7 Graft
excision
Sp4l Irradiated
grafts
Sp4l Irradiated
cells
generations
17
17
26
Route dc
s.c. 2x
5x
s.c.
2x
s.c. 2x
55-58 i.m.
5x
9 s.c.
17-20 s.c. 5 x
49-53 i.m.
4 x
:se generation Route
104 16 s.c.
i.p.
1.v.
105 19 S.C.
i.p.
i.v.
105 21 s.c.
106 20 i.v.
106 24 i.v.
104 28 s.c.
i.p.
102 60 i.m.
103 s.c.
105 10 S.C.
i.p.
i.v.
104
103
103
rats
0/5
0/5
0/4
0/5
0/5
1/3
0/5
0/4
0/4
3/4
4/4
1/5
3/4
1/4
2/5
3/4
(65 + 56)
21 s.c. 1/5
i.p. 2/3
i.v. 5/6
(>200)
54 i.m. 2/5
s.c. 1/4
controls
2/4
4/4
0/4
2/4
4/4
1/4
4/4
2/4
4/4
2/3
2/4
5/5
5/6
4/4
4/4
4/4
(108+4)t
4/4
4/4
4/4
(> 200)t
2/6
1/5
p
<0-02
<0-02
<0-02
<0-02
<0-05
<0-05
* Graft excision = surgical excision of s.c. tumour grafts; Irradiated grafts = immunization with trocar
grafts of tumour tissue inactivated by 150 Gy-irradiation; Irradiated cells =immunization with irradiated
(150 Gy) trypsinized tumour cell suspensions.
t Numbers in parentheses = mean number of visible lung nodules + s.e. per rat. Numbers in excess of 200
were not counted.
TABLE IV.-Immune response toformalin-treated sarcoma cells
Immunization
Cell-dose Injection Transplant
Tumour sequence route generation
Challenge inocula (s.c.)
Cell Transplant
dose generation
Tumour incidence
Treated Untreated
Sp7 5 x 107
8X 107
6x 107
2-5 x 107
2-7 x 107
2-2 x 107
1-3 x 107
Sp4l 5 x 107
6x 107
2 x 107
4x 107
i.p.
i.p.
i.p.
S.C.
i.p.
S.C.
i.p.
i.p.
S.C.
i.p.
S.C.
13
14
13
19
20
21
22
12
12
13
14
105 15 0/4 4/4 P<0-03
2x 104
5x 104
22 5/5* 4/4
15 3/5 4/5
* The immunized group developed high levels of circulating anti-tumour antibody (see text).
absence of tumour. However, where
tumour growth occurred, it progressed at
similar rates in both immunized and con-
trol rats. Intravenous challenge required
relatively high numbers of tumour cells to
produce reproducible growth in controls.
This meant that it might not be suitable
for demonstrating weak levels of im-
munity, although it was successful in one
graft-excision experiment with Sp7. I.m.
Sp7
Sp24
Sp24
Sp4l
Graft
excision
Graft
excision
Irradiated
cells
Graft
excision
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TABLE V.-Immunization with mitomycin-C-treated sarcoma cells
Immunization*
No. of
Tumour injections
Sp7 1
Sp24 5
5
5
1
5 Sp41
Cell Transplant
dose generation
106 46
106
107
107
106
107
63
43-47
69-73
59
67-71
Challenge inocula (s.c.)
Cell Transplant
dose generation
2 x 104 48
2 x 104
2x 104
2x 104
104
2 x 104
66
48
74
62
22
Tumour incidence
(-A-
Immunized Untreated
rats rats
6/6 6/6
6/6 6/6
6/6 6/6
3/5 4/5
2/4 3/5
4/5 3/5
* Cells were treated with mitomycin-C at 80 /g/ml and injected i.p.
TABLE VI.-Growth oftumour challenge inoculain ratspre-treated with vaccines containing
tumour cells and bacterial adjuvants
Immunizing inocula (s.c.)*
,, _
No. of
Tumour cells
Sp24 105
Bacterialt
adjuvant
BCG
BCG
105 BCG
BCG
105 BCG
BCG
No. of
injections
1
1
Days
between
injections
Tu
inc]
1
1
4
4
10
10
2 x 104 C. parvum 1
C. parvum 1
2 x 104 C. parvum 4
C. parvum 4
Sp4l 2 x 105 BCG
BCG
4
4
14
14
14
14
2 x 105 C.parvum 1
C. parvum 1
2 x 105 C. parvum 4
C. parvum 4
14
14
Challenge inocula (s.c.)t
mour Cell Tumour
idence dose incidence
0/5 2 x 104 4/5
2 x 104 2/4
2 x 104 2/4
0/6 2 x 104 6/6
2 x 104 6/6
2 x 104 6/6
5/6 2 x 104 1/1
2 x 104 6/6
2 x 104 6/6
2/5 104 0/3
104 4/4
104 4/4
2/5 104 1/3
104 5/5
104 5/5
3/6 5x 104 3/3
5x 104 6/6
5x 104 6/6
1/5 5x 104 4/4
5x 104 5/5
5x 104 5/5
1/5 5x 104 4/4
5x 104 5/5
5x 104 5/5
* Where both tumour cells and adjuvant were administered they were given in admixture.
t Rats in which the immunizing inocula grew unsuppressed were not challenged.
t BCG=Viable Glaxo percutaneous BCG (0 5 mg/injection).
CP =Heat-killed Burroughs Wellcome Corynebacterium parvum (07mg/injection).
challenge was superior to s.c. cellhange in cells forimmunization werethenevaluated
demonstrating resistance to Sp24 cells in (Tables IV, V and VI). The results oftests
rats immunized by prior i.m. injection of for immunogenicity of formalin-treated
irradiated Sp24 cells. However, since s.c. Sp7 and Sp4l cells are shown in Table IV.
challenge was more generally successful, Two experiments used Sp7, and in the
it was adopted in all subsequent experi- first of these, treatment with fairly high
ments. numbers of formalized tumour cells in-
Alternative methods of inactivating duced immunity to challenge with 105
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viable cells. In the second experiment
lower numbers of cells were used, and no
resistance to challenge was observed, but
all treated rats developed high levels of
circulating anti-Sp7 antibody detectable
both by membrane immunofluorescence
and an isotopic antiglobulin assay using
viable target cells (Middle & Embleton,
in preparation). No immune responses
against Sp4l could be detected in rats
treated with formalized cells. Attempted
immunization with cells attenuated by
mitomycin C failed to induce immunity to
Sp7, Sp24 or Sp4l (Table V). Experiments
were also carried out in which immune
responses were evaluated following sup-
pression of tumour growth by contact
with the bacterial adjuvants BCG and
C. parvum. These agents have previously
been known to be capable of suppressing
the growth of many types of tumour cells
placed in contact with them (Baldwin &
Pimm, 1978; Milas & Scott, 1978). In
pilot experiments, Sp7 proved to be diffi-
cult to control with admixed BCG or
C. parvum and insufficient numbers of
tumour-free rats were obtained to evaluate
tumour-immune responses by viable-cell
challenges. However, Sp24 and Sp4l
could be suppressed by both agents, and
results of rechallenging the animals with
the immunizing tumours are shown in
Table VI. With Sp24, immunization with
tumour cells and BCG produced no im-
munity to further challenge, but after
treatment with cells suppressed by contact
with C. parvum challenge with 104 Sp24
cells failed to produce tumours. This
effect, however, was not statistically sig-
nificant (P > 0.05). Immunity could not be
demonstrated with Sp41 even though the
latter appeared to be more antigenic than
Sp24 in previous tests (Tables I and II).
A limited number of cross-challenge
tests were performed in order to determine
whether induced immunity to the spon-
taneously-arising sarcomas was due to
individual or cross-reacting antigens
(Table VII). Animals immunized with
irradiated Sp7 cells were challenged with
either Sp7, Sp24 or Sp4l cells, using com-
parable cell doses. These animals rejected
105 Sp7 cells, but succumbed to a similar
dose of Sp4l cells or 4 x 104 Sp24 cells.
Conversely, rats similarly immunized with
irradiated Sp24 or Sp4l cells were not able
to reject 2 x 104 Sp7 cells. These results
indicate that immunity to Sp7 was in-
duced by an individually specific antigen
rather than a shared antigeni.
DISCUSSION
The results of our immunogenicity
tests clearly demonstrate that some spon-
taneously arising rat tumours possess
tumour-associated antigens capable of
inducing a tumour rejection response in
syngeneic hosts. This has previously been
observed with a number of different spon-
taneous tumours in the same rat strain
(Baldwin, 1966; Baldwin & Embleton,
1969). However, it is equally true that
such immunogenic spontaneous tumours
are in the minority. The sarcomas in the
present series all arose before June 1976,
during a long period of moderate rat
breeding and low spontaneous tumour
incidence. From June 1976 followed a
period of about 3 years, in which breeding
TABLE VII.-Specificity ofimmnunity to sarcoma Sp7 induced with irradiated tumour cells
Immunization* Challenge (s.c.)
No. of Cell Transplant Cell Transplant
Tumour injections dose generation Tumour dose generation
Sp7 4 3-15 x 106 25-31 Sp7 105 45
Sp24 4 x 104 46
Sp41 105 46
Sp24 4 1-10 x 106 40-45 Sp7 2 x 104 32
Sp4l 4 5-10x 106 41-45 Sp7 2 x 104 32
* Irradiated (150 Gy) cells were injected weekly i.p.
Tumour incidence
Tumour- Untreated
immunized controls
0/4 5/5 P< 0-02
6/6 3/6
6/6 5/5
6/6 6/6
6/6 6/6
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was intensified to produce large numbers
of rats, and this, combined with more
vigilant examination of breeders, led to a
higher rate of accumulation of spon-
taneous tumours. These were the subject
of a larger immunogenicity-screening pro-
gramme with essentially negative findings
(Middle & Embleton, in preparation).
This, together with the observation that a
relatively small proportion of rat mam-
mary tumours were antigenic in previous
work (Baldwin & Embleton, 1969), leads
us to conclude that most spontaneous rat
tumours are not detectably immunogenic
in syngeneic hosts, but there are notable
exceptions. In this study, for example,
sarcomas Sp7 and Sp4l were characterized
by weak, but detectable, tumour-asso-
ciated antigens. In the case of Sp7 this
antigen was individually specific and not
shared by Sarcomas Sp4l or Sp24. This
confirms observations of Hammond et al.
(1967), who showed that antigens asso-
ciated with spontaneous mouse sarcomas
or myoepitheliomas were tumour-specific,
and Baldwin & Embleton (1969), who
demonstrated the unique antigenicity of
3 spontaneous rat mammary carcinomas.
One possible explanation for the nega-
tive immunogenicity of 2 other sarcomas
in our study is that the techniques used
for their demonstration were inadequate.
However, this is probably not the case,
because several different methods of
immunization and challenge were evalu-
ated. Our standard methods of immuniza-
tion by excision of tumour grafts or
implantation of 150 Gy irradiated tissue
followed by s.c. challenge at growth
threshold levels (Tables I and II) proved
to be optimum for the demonstration of
antigens on the positive tumours. Anti-
gens other than transplantation antigens
can sometimes be detected on spon-
taneous tumours by in vitro tests (Baldwin
& Embleton, 1974) but these are of doubt-
ful significance with regard to tumour
immunity. Another reason may be that
antigens on these tumours preferentially
induce suppressor responses rather than
efficient effector responses. This possi-
bility has been explored with some of the
apparently non-immunogenic tumours and
no evidence of suppressor responses could
be found (Middle et al., unpublished). It
therefore seems most likely that the poor
immunogenicity of most spontaneous
tumours reflects a lack of tumour-asso-
ciated rejection antigens or a deficiency in
their expression at the cell surface.
This has led to criticism of the value of
immunotherapy against tumours (Hewitt,
1978, 1979). Pimm et al. (1978) showed
that BCG could suppress the growth of
some spontaneous rat tumours ifthey were
injected s.c. in admixture (contact sup-
pression) but specific active immuno-
therapy of tumour at a distant site was
unsuccessful, except in the case of a single
mammary carcinoma (Sp4) which was
previously shown to be fairly strongly
immunogenic (Baldwin & Embleton,
1969). Similar results were obtained in
later experiments using C. parvum instead
of BCG (Willmott et al., 1979). In the
present studies immunity to rechallenge
was evaluated in rats the tumours of
which were suppressed by contact with
BCG or C. parvum, and it was found that
in most cases they failed to reject the
challenge inoculum. Contact suppression
probably involves local host mechanisms
(Bartlett et al., 1972; Moore et al., 1975;
Pimm et al., 1978) but therapy of tumour
at a distant site probably includes a com-
ponent of systemic anti-tumour immunity
(Greager & Baldwin, 1978), so these re-
sults are not encouraging with regard to
immunotherapy of distant tumour de-
posits. Analogies have been drawn between
spontaneous animal tumour models and
human tumours (Hewitt, 1978, 1979) and
in this context it is apparent that immuno-
therapy of human tumours with bacterial
adjuvants has not lived up to early
expectations (Baldwin, 1979).
The relevance of spontaneous animal
tumours to human cancer cannot be
stated with certainty, but there is support
for the belief that they are more closely
comparable with the human disease than
are most artificially induced models. As
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pointed out by Hewitt et al. (1976), it is
thus important to exercise caution in the
extrapolation of data obtained with
highly immunogenic models. Since detect-
able levels of immunity can be induced
against a proportion of spontaneous
tumours, however, it is equally important
not to adopt too negative an attitude, but
to continue to exploit new approaches
which stand a chance of increasing host
resistance against them.
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